it's not the company nothing has changed. It's the overall market can guys see?
The recent insider buying makes me believe that another deal is on its way.
Yang is on the board of AstraZeneca that's another 76 billion market cap.
now that liquidity issue is solved.
Goldman Sachs will put it on its strong buy list boo yeah.
Sentiment: Strong Buy
kbrion77thanks;Some investor has yet to realize the potential of their technology.
cdxs deliver significant cost savings and yield improvements for industrial-scale production of their technology.
Shell has invested hundreds of millions in developing CodeEvolver technology.
CDXS is pursuing major niche markets that have billion dollar annual revenue potential and very little in the way of potential competition.if CDXS succeeds in any of these markets its revenues could quickly ramp into the hundreds of millions per year and if a couple of them come together revenues in excess of a billion won't take much for example in the food industry,Nestle, Mondelez, Coca-Cola, Pepsi, United food, General Mills. Kellogg. these are some of the biggest in the pharmaceuticals Johnson & Johnson Pfizer Merck these all are multibillion Billion$$ Giants just to name a few out of hundreds.
CDXS has a very bright future.
No pumping intended.
For long-term investors, please do your self a favor read Fully into these deals CDXS is making using their CodeEvolver technology.
Here is a few examples.
1-- Merck has been their client for many years and fully satisfied with CDXS Under the terms of the agreement, Merck has a non-exclusive license to use the CodeEvolver protein engineering platform technology to develop novel enzymes for use in the manufacture of Merck's pharmaceutical products. Codexis is eligible to receive up to $18M over the next 15 - 24 months, $5M up front and $13M related to certain technology transfer milestones. IT IS ALSO ELIGIBLE TO RECEIVE UP TO A MAXIMUM OF $15 M FOR EACH PHARMACEUTICAL INGREDIENT USING NOVEL ENZYMES developed with CodeEvolver..
2---GSK will pay Codexis up to $25 million over the next two years, including $6 million upfront and an additional $19 million once specific tech transfer milestones are reached. If GSK's application of the technology leads to successful projects, which is more likely MERCK is a good example for the last a few years. CODEXIS COULD GET EVEN MORE MILESTONE PAYMENTS RANGING FROM $5.75 MILLION TO $38.5 MILLION PER PROJECT. Plus, Codexis could also pick up royalties based on net sales of a limited set of products GSK develops using CodeEvolve not to mention other biocatalysts deals including the food industry.
These deals are just icy on the cake I bet you that they will have at least couple of more deals within the next two quarters.
After the market closed, go to their website on the investor relations you can listen to the replay.
I was too late when I called to get in but the lady told me they had good Q&A.
Sentiment: Strong Buy